Search Results - "Penza, S"

Use of the McIsaac Score to Predict Group A Streptococcal Pharyngitis in Outpatient Nurse Phone Triage and Electronic Visits Compared With In-Person Visits: Retrospective Observational Study by Pecina, Jennifer L, Nigon, Leah M, Penza, Kristine S, Murray, Martha A, Kronebusch, Beckie J, Miller, Nathaniel E, Jensen, Teresa B

“…The McIsaac criteria are a validated scoring system used to determine the likelihood of an acute sore throat being caused by group A streptococcus (GAS) to…”
Get full text

Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy by Vasu, S, Wu, H, Satoskar, A, Puto, M, Roddy, J, Blum, W, Klisovic, R, Andritsos, L, Hofmeister, C, Benson, D M, Efebera, Y, Jaglowski, S, Penza, S, Cohen, D, Devine, S, Cataland, S

Get full text

Combination of the PD‐1 inhibitor Nivolumab and Immunomodulatory Drug Lenalidomide in Relapsed Hodgkin and Large B‐cell Lymphoma: Results from a Phase I/II Study by Bond, D. A., Wei, L., Yildiz, V., Reneau, J., Sawalha, Y., Christian, B., Brammer, J., Epperla, N., Koff, J., Dendorfer, A., Yang, L., Baiocchi, R., Voorhees, T., Sigmund, A. M., Hanel, W., Shindiapina, P., Denlinger, N., Penza, S., Jaglowski, S., Bezerra, E., Alinari, L., Blum, K. A, Maddocks, K.

Get full text

A single center’s experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation by Haverkos, B M, Huang, Y, Elder, P, O'Donnell, L, Scholl, D, Whittaker, B, Vasu, S, Penza, S, Andritsos, L A, Devine, S M, Jaglowski, S M

“…In an otherwise eligible patient with relapsed lymphoma, inadequate mobilization of hematopoietic stem cells (HSCs) is a limiting factor to proceeding with an…”
Get full text

The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma by Jaglowski, S M, Ruppert, A S, Hofmeister, C C, Elder, P, Blum, W, Klisovic, R, Vasu, S, Penza, S, Efebera, Y A, Benson, D M, Devine, S M, Andritsos, L A

“…Patients who undergo autologous stem cell transplant (ASCT) for hematologic malignancies frequently have multiple comorbidities. The hematopoietic cell…”
Get full text

Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma by Cohen, J B, Hall, N C, Ruppert, A S, Jones, J A, Porcu, P, Baiocchi, R, Christian, B A, Penza, S, Benson, D M, Flynn, J, Andritsos, L A, Devine, S M, Blum, K A

“…Positron emission tomography/computed tomography (PET/CT)-positive findings before autologous SCT (auto-SCT) are associated with inferior PFS and OS in…”
Get full text

PHASE I DOSE‐ESCALATION STUDY OF VENETOCLAX PLUS BEAM FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR CHEMORESISTANT, RELAPSED/REFRACTORY, OR HIGH‐RISK NON‐HODGKIN'S LYMPHOMA (NHL); PRELIMINARY RESULTS by Maakaron, J., Zhao, Q., Puto, M., Von Derau, R., Robinson, J., Brammer, J., Penza, S., Baiocchi, R., Christian, B., Maddocks, K., Saad, A., Wall, S., Benson, D., Efebera, Y., Rosko, A., Ayyappan, S., Grieselhuber, N., Vasu, S., Larkin, K., Epperla, N., Devarakonda, S., Choe, H., Chaudhry, M., Blaser, B., Blachly, J., Bhatnagar, B., Alinari, L., Mims, A., Jaglowski, S., William, B.M.

Get full text

An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor by Haverkos, B M, McBride, A, O'Donnell, L, Scholl, D, Whittaker, B, Vasu, S, Penza, S, Andritsos, L A, Devine, S M, Jaglowski, S M

“…In an otherwise eligible patient, inadequate mobilization of PBSCs is a limiting factor to proceeding with an auto-ASCT. In such situations, plerixafor is…”
Get full text

Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation by COPELAN, E. A, BECHTEL, T. P, AVALOS, B. R, ELDER, P. J, EZZONE, S. A, SCHOLL, M. D, PENZA, S. L

“…Long-term outcome was analyzed in 28 patients transplanted between 1989 and 1992 following busulfan and cyclophosphamide and who had busulfan levels studied…”
Get full text

Comparison of eVisit Management of Urinary Symptoms and Urinary Tract Infections with Standard Care by Murray, Martha A, Penza, Kristine S, Myers, Jane F, Furst, Joseph W, Pecina, Jennifer L

“…Urinary symptoms and urinary tract infections (UTIs) are common complaints for which women seek health care. Evolving modalities of care delivery have shifted…”
Get more information

Electronic Visits for Minor Acute Illnesses: Analysis of Patient Demographics, Prescription Rates, and Follow-Up Care Within an Asynchronous Text-Based Online Visit by Penza, Kristine S, Murray, Martha A, Pecina, Jennifer L, Myers, Jane F, Furst, Joseph W

“…Patients can obtain medical advice and treatment from a healthcare provider asynchronously through an electronic visit (eVisit) within a secure online portal…”
Get more information

Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma by COPELAN, E. A, PENZA, S. L, EZZONE, S. A, O'DONNELL, L. C, TIGHE, M. B, RISLEY, G. L, YOUNG, D. C, BOLWELL, B. J, POHLMAN, B, AVALOS, B. R, GOORMASTIC, M, ANDRESEN, S. W, KALAYCIO, M, BECHTEL, T. P, SCHOLL, M. D, ELDER, P. J

“…The purpose of the study was to determine the toxicities and effectiveness of a novel preparative regimen of busulfan (Bu) 14 mg/kg, etoposide 50 or 60 mg/kg,…”
Get full text

Second autologous stem cell transplant for multiply relapsed Hodgkin's disease by LIN, T. S, AVALOS, B. R, PENZA, S. L, MARCUCCI, G, ELDER, P. J, COPELAN, E. A

“…Therapeutic options for patients with Hodgkin's disease who relapse after high-dose chemotherapy with autologous stem cell support are limited. Salvage…”
Get full text

Diffuse alveolar hemorrhage following gemtuzumab ozogamicin by Lin, T S, Penza, S L, Avalos, B R, Lucarelli, M R, Farag, S S, Byrd, J C, Copelan, E A

Get full text

Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease by Copelan, E A, Ceselski, S K, Ezzone, S A, Lasky, L C, Penza, S L, Bechtel, T P, Klein, J L, Hehmeyer, D M, Scholl, M D, Marshall, D D, Elder, P J, Risley, G L, Avalos, B R

“…We analyzed the safety and effectiveness of high-dose etoposide (2 g/m2) followed by granulocyte colony-stimulating factor (G-CSF) as a peripheral-blood…”
Get more information

Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation by COPELAN, E. A, PENZA, S. L, ELDER, P. J, EZZONE, S. A, SCHOLL, M. D, BECHTEL, T. P, BELT, P. S, AVALOS, B. R

“…Prognostic factors in 42 patients aged 11 to 62 (median 46) years, with myelodysplastic syndrome (MDS) or after leukemic transformation, who underwent…”
Get full text

High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia by FARAG, S. S, BOLWELL, B. J, AVALOS, B. R, BYRD, J. C, COPELAN, E, ELDER, P. J, KALAYCIO, M, LIN, T, POHLMAN, B, PENZA, S, MARCUCCI, G, BLUM, W, SOBECKS, R

“…To reduce relapse following allogeneic transplantation for AML, intensification of high-dose busulfan/cyclophosphamide using additional agents has been…”
Get full text

Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation by COPELAN, E, HOSHAW-WOODARD, S, LEMESHOW, S, AVALOS, B, ELDER, P, PENZA, S, FARAG, S, MARCUCCI, G, LIN, T, EZZONE, S, SCHOLL, M. D, BECHTEL, T

“…The use of VP-16 for stem cell mobilization has been cited as a significant risk factor for the development of therapy-related myelodysplasia/leukemia…”
Get full text

The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy by COPELAN, E. A, PENZA, S. L, AVALOS, B. R, THEIL, K. S, ELDER, P. J, BECHTEL, T. P, TIGHE, M. B, EZZONE, S. A, SCHOLL, M. D, BELT, P. S, YOUNG, D. C

“…Results in 164 patients who underwent allogeneic marrow transplantation following busulfan and cyclophosphamide over a 15 year period were analyzed. Age…”
Get full text

Busulfan, Cyclophosphamide, Etoposide (BUCYVP) or Carmustine, Etoposide, Cytarabine, Melphelan (BEAM) for Conditioning Prior to Autologous Stem Cell Transplantation (ASCT) in Patients with Hodgkin Lymphoma (HL)? by Salem, G, Ruppert, A.S, Efebera, Y, Elder, P, Bingman, A, Penza, S, Andritsos, L.A, Devine, S.M

Get full text